This study examines the biocompatibility of 11 modern wound dressings (WDs)―Syspur-derm^®, Parapran^®, Lomatuell^®H, Voskopran^®, Metalline^®, Granuflex^®, Chitopran^®, HydroTac^®transparent, Branolind^®N, Aquacel^TM adhesive foam, Aquacel^TMAg⁺―developed for the treatment of acute and chronic wounds, and their potential use as secondary WD for the hydrogel-based bioengineered skin equivalent (BSE) “Equivalent Dermal, ED”. The study was conducted to better understand the properties of these WDs that influence the healing process. The biocompatibility of WDs was evaluated in vitro based on their effects on the viability of human dermal fibroblasts (DFs). The MTT assay, lifetime analysis of DFs’ morphological state, and analysis of their actin cytoskeletal organization using a WDs’ extracts showed that effects of WD on DFs varied among WDs. It has been revealed that WDs Parapran^®, Lomatuell^®H, Voskopran^®, Metalline^® and Chitopran^® have high biocompatibility and can be effectively used for wound treatment, whereas Granuflex^®, Syspyr-derm^®, HydroTac^® transparent, Branolind^®N, Aquacel^TM adhesive foam and Aquacel^TMAg⁺ have lower biocompatibility, so they could be used for wound therapy with caution. Only Parapran^® with chlorhexidine showed high biocompatibility with the BSE “The Dermal Equivalent, ED” and can be safely used in combination with it as a secondary WD.